Avecia
Nitto Denko Avecia is a privately held CDMO and subsidiary of Nitto Denko Corporation that develops and manufactures therapeutic oligonucleotides, serving pharmaceutical innovators from preclinical batches through commercial drug substance and drug product supply.
- Company typePrivate
- Founded1993
- HeadquartersMilford, United States
- Headcount501–1,000
- GTM typeB2B
- OfferingServices
What Avecia does
Nitto Denko Avecia, Inc. (operating as Nitto Avecia, previously Avecia) is a privately held Contract Development and Manufacturing Organization (CDMO) that specializes in therapeutic oligonucleotides. Founded in 1993 as the first CDMO dedicated to the oligonucleotide therapeutic market, the company is a wholly-owned subsidiary of the Japanese conglomerate Nitto Denko Corporation. It operates two FDA-inspected, ISO 8 GMP facilities: a headquarters and manufacturing site in Milford, Massachusetts, and a manufacturing site in Cincinnati, Ohio, where the company most recently cleared an FDA inspection with no observations (August 2024) and achieved ANVISA GMP certification in July 2025.
Nitto Avecia offers a full-spectrum service portfolio covering preclinical manufacturing (OliGrow®, 100 mg to 25 g), analytical development, process development, drug substance manufacturing (up to 1,600 mmol synthesis capacity), process performance qualification, and quality control/stability testing. Through its partnership with Nitto Avecia Pharma Services, it extends into drug-product manufacturing, providing an end-to-end oligonucleotide supply chain. The company has manufactured over 1,200 oligonucleotide sequences and claims the most extensive late-phase portfolio among oligonucleotide CDMOs.
Revenue is generated through professional-services and commercial-supply contracts with pharmaceutical and biopharmaceutical innovators under flexible Master Services, Supply, and Quality Agreement structures, with quote-based (non-public) pricing. Distribution is exclusively direct: dedicated Business Development Representatives and Project Managers engage enterprise buyers, supplemented by website, email outreach, and conference participation (OTS Annual Meeting, TIDES Europe/Asia). The company is actively investing in continuous-manufacturing platforms aligned with ISPE Pharma 4.0, a greener amidite/solvent-reducing process, and an evaluation agreement with Codexis to assess an enzymatic ECO Synthesis® platform for siRNA manufacturing.
Avecia firmographics
Firmographics- Name
- Avecia
- Legal name
- Nitto Denko Avecia, Inc.
- Website
- https://avecia.com
- Company type
- Private
- Founded year
- 1993
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- Nitto Denko Avecia is a privately held CDMO and subsidiary of Nitto Denko Corporation that develops and manufactures therapeutic oligonucleotides, serving pharmaceutical innovators from preclinical batches through commercial drug substance and drug product supply.
- Ownership category
- akta.pro rank
Avecia industry classification
Industry- Product category
- Biopharmaceutical Contract Manufacturing (CDMO)
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC) (HLAAADAF)
- akta.pro secondary industry
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
Keywords
Where Avecia is headquartered
LocationHeadquarters
- HQ city
- Milford
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Avecia business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Infrastructure, Technology or R&D, Supply Chain, Operations, Marketing or Sales
Revenue model
- Contract Development and Manufacturing (CDMO) Services: Nitto Avecia generates revenue through providing contract manufacturing services for oligonucleotide therapeutics. Services span preclinical manufacturing (OliGrow®), analytical development, process development, drug substance manufacturing, process performance qualification, and quality control/stability testing. The company operates as a CDMO with flexible agreement structures including Master Services, Supply, and Quality Agreements.
- Commercial Manufacturing Supply: Long-term commercial supply of oligonucleotides, with the company having been equipped to support commercial launches since 2005 and currently manufacturing commercial supplies of oligonucleotides.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | OliGrow Preclinical Service - Non-GMP oligonucleotide manufacturing |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
Avecia product offering
Product offeringCore offering
Nitto Avecia is a Contract Development and Manufacturing Organization (CDMO) specializing in oligonucleotide therapeutics. It provides preclinical manufacturing (OliGrow®), analytical development, process development, drug substance manufacturing, process performance qualification (PPQ), and quality control/stability services. In partnership with Nitto Avecia Pharma Services, it offers an end-to-end oligonucleotide solution from drug substance through drug product manufacturing.
Product overview
Nitto Avecia operates as a Contract Development and Manufacturing Organization (CDMO) specializing in oligonucleotide therapeutics. The company offers a comprehensive service portfolio centered around OliGrow® for preclinical manufacturing, paired with Analytical Development, Process Development, Drug Substance Manufacturing, Process Performance Qualification (PPQ), and Quality Control/Stability services. In partnership with Nitto Avecia Pharma Services, the company provides end-to-end solutions extending from drug substance through drug product manufacturing, making it the first CDMO to offer this complete oligonucleotide development and commercial manufacturing pathway. Services span from 100 mg preclinical batches through commercial-scale production up to 1600 mmol synthesis capacity.
Differentiator
Problem solved
Functional benefit
Products and services
- OliGrow® Preclinical Manufacturing Preclinical manufacturing service providing custom oligonucleotide synthesis for non-cGMP applications with batch sizes from 100 mg to 25 g, leveraging experience from over 1,200 different therapeutic oligonucleotide sequences. Targeted at pharmaceutical innovators preparing material for preclinical studies.
- Analytical Development Comprehensive analytical services covering method development, transfer, validation, ICH stability studies, and CMC documentation support for regulatory filings. Includes LC-ESI-MS/MS sequencing for oligonucleotides up to 30 bases with 100% coverage and enzyme digestion followed by LC-ESI-MS/MS for sequences over 35 bases.
- Process Development Development services supporting oligonucleotide therapeutic development from lab to validation and commercial manufacture, utilizing the OliGO program for advanced starting points leveraging extensive process knowledge.
- Drug Substance Manufacturing Oligonucleotide manufacturing with synthesis and downstream processing assets supporting batches from a few mmols up to 1600 mmol, with ISO8-qualified HEPA-filtered manufacturing suites and multiple cGMP manufacturing trains at Milford and Cincinnati locations.
- Process Performance Qualification (PPQ) Risk-based validation and PPQ services using Design of Experiments (DoE) for small-scale modeling, characterization activities, and execution of PPQ batches through the Validation Master Plan.
- Quality Control / Stability cGMP testing services for raw materials, intermediates, and crude API including duplexes and conjugates, with comprehensive stability study services, reference standard testing, and microbiology support including environmental sampling.
Quantifiable outcome
- FDA inspection with no observation result at Cincinnati facility (August 2024)
- +2 more outcomes
Companies that use Avecia
Customer profileSegments2 records
Ideal customer profiles1 record
Avecia technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Avecia partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Avecia Pharma ServicescoreIn partnership with Avecia Pharma Services, Nitto Avecia is the first CDMO to offer a comprehensive, end-to-end oligonucleotide solution. This partnership provides a single expert partner handling the entire process from drug substance through drug product manufacturing.
Scale indicators9 records
Recent moves7 records
Expansion highlights5 records
Avecia competitors and assessment
Company assessmentBroad incumbents
- Agilent Technologies (Oligonucleotide Manufacturing): A large life-sciences instrumentation and services company that operates an oligonucleotide manufacturing solutions business serving therapeutic and diagnostic oligo developers, overlapping directly with Nitto Avecia's synthesis and analytical services.
- Eurofins Genomics / Eurofins Discovery: A large contract services platform with custom oligonucleotide synthesis and nucleic-acid analytical services serving both research and therapeutic-grade customers, competing for preclinical and analytical development work.
- Thermo Fisher Scientific (Patheon CDMO): The global broad CDMO leader offering drug substance, drug product, and analytical services; it is expanding oligonucleotide manufacturing capabilities and competes for late-phase and commercial oligonucleotide manufacturing contracts.
- Catalent: A global CDMO offering drug substance and drug product services across modalities including nucleic-acid adjacencies; competes with Nitto Avecia for analytical, process development, and commercial manufacturing work for pharma innovators.
Direct peers
- BioSpring: A specialized oligonucleotide CDMO offering GMP oligonucleotide manufacturing and analytical services from preclinical through commercial scale, the most directly comparable pure-play peer to Nitto Avecia.
- Axolabs (a LGC company): LGC Group's oligonucleotide API CDMO focused on therapeutic nucleic acids including siRNA and antisense chemistries, serving the same pharmaceutical innovator client base from preclinical through commercial manufacture.
Emerging players
- STA Pharmaceutical (WuXi STA): The small-molecule CDMO arm of WuXi AppTec that has been expanding into oligonucleotide and nucleic-acid manufacturing, representing a scaled, well-capitalized new entrant targeting the same therapeutic oligo CDMO opportunity.
- Samsung Biologics: A large biologics CDMO that has been building nucleic-acid and oligonucleotide manufacturing capacity as part of its diversification, increasingly competing for therapeutic oligo CDMO business at commercial scale.
- CordenPharma: A full-service API CDMO with peptide and oligonucleotide capabilities that serves pharmaceutical innovators across development and commercial stages, overlapping on oligonucleotide API manufacturing and related analytical services.
Others
- Codexis: An enzyme-engineering company whose ECO Synthesis® enzymatic platform for siRNA manufacturing is being jointly evaluated with Nitto Avecia; not a CDMO competitor directly but a potential disruptive technology partner that could reshape oligonucleotide manufacturing economics.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Avecia social profiles
Digital presenceAvecia compliance and trust
Trust signalCompliance6 records
Avecia financial estimates
Financial estimateRevenue estimate
Valuation estimate
Avecia leadership team
Management profileNumber of profiles
Profiles20 records
Avecia funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Avecia M&A and investment
M&A and investmentM&A4 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Avecia
What does Avecia do?
Nitto Avecia is a Contract Development and Manufacturing Organization (CDMO) specializing in oligonucleotide therapeutics. It provides preclinical manufacturing (OliGrow®), analytical development, process development, drug substance manufacturing, process performance qualification (PPQ), and quality control/stability services. In partnership with Nitto Avecia Pharma Services, it offers an end-to-end oligonucleotide solution from drug substance through drug product manufacturing.
Is Avecia a public or private company?
Avecia is a private company. It is classified as corporate owned and is currently operating.
When was Avecia founded?
Avecia was founded in 1993. It employs 501 to 1,000 people.
Where is Avecia based?
Avecia is headquartered in Milford, United States, in the North America region.
How does Avecia make money?
Two revenue lines are on record. Contract Development and Manufacturing (CDMO) Services are the primary driver. The others are commercial Manufacturing Supply.
Who are Avecia's main competitors?
Broad incumbents on record are Agilent Technologies (Oligonucleotide Manufacturing), Eurofins Genomics / Eurofins Discovery, Thermo Fisher Scientific (Patheon CDMO) and Catalent. Direct peers are BioSpring and Axolabs (a LGC company). Emerging players are STA Pharmaceutical (WuXi STA), Samsung Biologics and CordenPharma. Codexis is listed as an others.
Does Avecia have an API?
No public API is recorded for Avecia.
What industry is Avecia in?
Avecia's product category is Biopharmaceutical Contract Manufacturing (CDMO). Its primary akta.pro industry code is HLAAADAF, RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC), with a secondary code of HLAGABAG, Drug Substance–Drug Product Integrated CDMO. Its NAICS code is 325412 and its SIC code is 2834.